Status:
COMPLETED
Target Weaning Oxygen to Determine Cafffeine Duration for AOP
Lead Sponsor:
Children's Hospital of Chongqing Medical University
Conditions:
Apnea of Prematurity
Caffeine
Eligibility:
All Genders
14-6 years
Phase:
PHASE4
Brief Summary
Caffeine, a typical representative of methylxanthine, is world-widely used to manage apnea of prematurity (AOP) in neonatology. However, an appropriate medication regimen of caffeine has not been well...
Eligibility Criteria
Inclusion
- premature infants with gestational age \<30 weeks
- postmenstral age ≥32weeks
- a history of caffeine therapy
- no current positive pressure respiratory support, and free of apnea for at least five consecutive days, but still oxygen dependent
- parents or legal guardians sign informed consent to attend this study
Exclusion
- congenital cardiorespiratory malformation, or chromosomal abnormalities
- Grade III/IV intraventricular hemorrhage, or probable brain injury attributable to confirmed central nervous system infection, severe periventricular leukomalacia or other entities;
- underwent tracheostomy
- currently on sedatives, opioids, or other medication related to depressed breath
Key Trial Info
Start Date :
May 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 15 2023
Estimated Enrollment :
310 Patients enrolled
Trial Details
Trial ID
NCT04868565
Start Date
May 1 2021
End Date
October 15 2023
Last Update
October 18 2023
Active Locations (41)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital of USTC（University of Science and Technology of China）
Hefei, Anhui, China
2
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
3
Yuan Shi
Chongqing, Chongqing Municipality, China, 400014
4
First Affiliated Hospital of Army Military Medical University
Chongqing, Chongqing Municipality, China